Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

EJNMMI Research

Table 3 Rate of severe haematological adverse events during 2 cycles of PSMA-RLT among all patients (n = 64) and different subgroups

Haematological parameter	CTCAE grade 3 during 2 cycles of PSMA-RLT [%] among:
	All patients (n = 64)	a) miM1b (uni/oligo) (n = 13)	b) miM1b (diss/dmi) (n = 51)
	All patients (n = 64)	a) miM1b (uni/oligo) (n = 13)	biochemical response (n = 16)^a	Biochemical non-response (n = 35)^a
Anaemia	8	0	0	8
Thrombopenia	3	0	0	3
Leukopenia	2	0	0	2

CTCAE = Common Toxicity Criteria for Adverse Events version 5.0 [10], miM1b = bone involvement categorised according to PROMISE criteria [25]
^aAccording to Prostate Cancer Working Group criteria v. 3 [20]